Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock—A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study)

Anaphylatoxin C5a, a proinflammatory complement split product, plays a central role in mediating organ dysfunction. OBJECTIVES: This phase II clinical trial was conducted to study safety, tolerability, pharmacokinetics, and pharmacodynamics of vilobelimab, a recombinant monoclonal antibody against C...

Descripción completa

Detalles Bibliográficos
Autores principales: Bauer, Michael, Weyland, Andreas, Marx, Gernot, Bloos, Frank, Weber, Stephan, Weiler, Norbert, Kluge, Stefan, Diers, Anja, Simon, Tim Philipp, Lautenschläger, Ingmar, Gründling, Matthias, Jaschinski, Ulrich, Simon, Philipp, Nierhaus, Axel, Moerer, Onnen, Reill, Lorenz, Jörres, Achim, Guo, Renfeng, Loeffler, Markus, Reinhart, Konrad, Riedemann, Niels
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601347/
https://www.ncbi.nlm.nih.gov/pubmed/34806021
http://dx.doi.org/10.1097/CCE.0000000000000577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601347/
https://www.ncbi.nlm.nih.gov/pubmed/34806021
http://dx.doi.org/10.1097/CCE.0000000000000577

Ejemplares similares